Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
131I-FAPi-5
- Development stage
- Preclinical
- Lead developer
- University of Copenhagen
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
131I-FAPi-5 is a dimeric radiopharmaceutical designed for targeted radionuclide therapy (TRT) of tumors expressing fibroblast activation protein (FAP). It consists of two FAP-targeting inhibitor (FAPi) subunits linked and labeled with the beta-emitting radioisotope Iodine-131 (131I) via a tetrazine-trans-cyclooctene (T4CO) ligation method. This dimeric structure is engineered to enhance tumor retention and increase the radiation dose delivered to the tumor microenvironment compared to monomeric counterparts. Preclinical evaluation in human glioblastoma (U87-MG) xenograft models has shown that 131I-FAPi-5 achieves high and sustained tumor uptake with primary renal excretion, leading to significant tumor regression and improved survival rates. It is being investigated as a scalable and cost-effective alternative to radiometal-based FAP therapies.
- Other names
- 131I-labeled FAPi dimerIodine-131 labeled FAP inhibitor dimerIodine131 labeled FAP inhibitor dimerIodine 131 labeled FAP inhibitor dimer
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 131I-FAPi-5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 131I-FAPi-5.